NewsRoom Articles - Page 172 of 214

FridayMar 05, 2021 11:13 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) Get the Green Light for Clinical Trials’ Protocols from Ethics Panels

CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44% CNSP has sublicensed Berubicin to WPD Pharmaceuticals in 31 countries primarily in eastern Europe and western Asia WPD plans to conduct a Phase 2 trial in adults with GBM and a Phase 1 trial for pediatric patients with malignant gliomas CNSP intends to conduct its own Phase 2, potentially pivotal, trial in s…

ThursdayMar 04, 2021 2:30 pm

Researchers Design New Device That Uses Body as a Battery

CU Boulder researchers have designed a low-cost wearable device that uses the human body as a biological battery. The device is made of a stretchy material that allows an individual to wear it as a bracelet, ring or other accessory. The device harnesses an individual’s natural heat and uses thermoelectric generators to turn the internal temperature of an individual’s body into electricity. The paper was published in the “Science Advances” journal. Associate professor at the Paul M. Rady Department of Mechanical Engineering, Jianliang Xiao, who is also the paper’s senior author, stated that the future objective of the researchers is…

ThursdayMar 04, 2021 1:29 pm

RYAH Group Committed to Advancing Telehealth in HIPAA-Compliant Environment

Telehealth sector going through explosive growth; patients' data protection remains key challenge Although relaxed due to COVID-19 outbreak, HIPAA guidelines protecting patients' data security, privacy likely to tighten as pandemic abates RYAH appears ready to respond to strict data security requirements, uses medical data in a HIPAA-compliant setting Telehealth is becoming increasingly popular with patients and doctors alike, but securing the integrity of patient information remains critical. As a company developing proprietary technology supporting a data-driven healthcare approach, RYAH Group appears ready to respond to the strict data security requirements. With patients needing more access to health care, and providers…

ThursdayMar 04, 2021 11:46 am

Brain Scientific (BRSF) Developing State-of-the-Art AI Diagnostic Analytics

BRSF working to improve diagnostics by leveraging AI and machine learning Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly. But BRSF isn’t stopping there. The company’s…

WednesdayMar 03, 2021 12:26 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Reimagines Technology to Create Better Cancer Outcomes

Archaic technology contributes to dismal recurrence rate in bladder cancer Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery There is potential to extend this technology to virtually other endoscopic procedures The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and…

WednesdayMar 03, 2021 12:15 pm

Hydrogel Injection Could Change Cardiac Tissue Healing After Heart Attacks

Researchers at Spain’s University of Valladolid, BIOFORGE Labs, the SFI Research Center and CÚRAM have created a hydrogel injectable that may prevent additional damage and assist in repairing heart muscles following a heart attack. Heart disease, or myocardial infarction, is the most common cause of death owing to irreversible damage of cardiac tissue after a heart attack. As tissue regeneration is minimal, any damage to heart muscle can’t be self-repaired. Present-day treatments lack an efficacious way to improve heart muscle repair and prevent death after a heart attack. The project’s lead, Professor Abhay Pandit, scientific director of CÚRAM, explained that…

TuesdayMar 02, 2021 2:57 pm

United Medical Equipment Business Solutions Network Inc. Stands to Benefit as Health Officials Call for More at Home Testing

Testing is more important than ever, medical experts claim, urging government to speed up widespread testing Tens of millions of rapid, at-home tests may be needed every day UME offers rapid testing kits to help end the pandemic, ready to seize the opportunity The U.S. government has announced plans to roll out more than 60 million home test kits to stop the COVID-19 virus from spreading (https://ibn.fm/O89KJ). United Medical Equipment Business Solutions Network (“UME”), a company offering a comprehensive line of COVID-19 products including rapid testing kits, stands ready to capitalize on the growing push for widespread testing and help…

TuesdayMar 02, 2021 2:13 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic About Upcoming Berubicin Trials After IND Approval

Berubicin is CNS Pharmaceuticals’ lead product candidate for treatment of Glioblastoma Multiforme, and has the potential to be the first anthracycline to cross the blood-brain barrier based on limited results from a Phase 1 trial The market for GBM treatment is estimated to reach $3.3 billion in 2024, growing at a CAGR of 17.4% CNS, in collaboration with sublicensee partner WPD Pharmaceuticals, is currently planning three Berubicin clinical trials, all to start within the year – two Phase II adult trials and a pediatric Phase I trial Glioblastoma Multiforme (“GBM”) is one of the most aggressive forms of brain cancer…

TuesdayMar 02, 2021 11:11 am

Researchers Find That Lower Temperatures Boost Coronavirus Transmission

The coronavirus pandemic has affected many industries and economies worldwide, in addition to causing the deaths of more than 500,000 people in America and 2.3-plus million people globally. Understanding how seasonal temperature changes affect virus transmission is crucial in decreasing the spread of the virus in the future. The virus that causes the coronavirus, SARS-CoV-2, is part of a larger coronavirus family, which aren’t spread as easily in warmer parts and during humid times in the year. Instead, the spread of these viruses increases in less humid times in cooler places. With this information in mind, researchers from the Joint…

MondayMar 01, 2021 2:15 pm

Pandemic Worsens ADHD in Kids, Experts Fear

Maggie Sibley, a clinical psychologist at the Center for Child Health, Behavior and Development at Seattle Children’s Research Institute, is worried about the effect the coronavirus pandemic has had on adolescents and children with hyperactivity/attention-deficit disorder as well as children experiencing depression and teens who may drop out of high school — and with good reason. Last year was difficult for many people, and perhaps more so for individuals who struggle with mental health and neurodevelopmental issues. Sibley explained that there were a lot more risk factors that may cause depression, adding that individuals with ADHD were at a higher…